Study #2011-0374
A Phase I Lead-in to a 2x2x2 Factorial Trial of Temozolomide, Memantine,Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
MD Anderson Study Status
Not Accepting
Treatment Agent
Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide
Description
This phase I trial studies the side effects and best dose of combination chemotherapy in treating patients with glioblastoma multiforme after radiation therapy. Drugs used in chemotherapy, such as temozolomide, memantine hydrochloride, and metformin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing them or stopping them from dividing. Mefloquine may help temozolomide, memantine hydrochloride, and metformin hydrochloride kill more cancer cells by making tumor cells more sensitive to the drug. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Study phase:
I
Physician name:
VINAYKUMAR Puduvalli
Department:
Neuro-Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.